Fundraising Fox
/Companies
Sign in

Elkedonia

4 known investors

Find your way into Elkedonia

Sign up to see every warm intro you have to Elkedonia

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Elkedonia team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Elkedonia is a biotech company developing a novel antidepressant treatment that targets intracellular neuroplasticity pathways rather than synaptic mechanisms, with the goal of providing rapid, long-lasting relief for depression patients. The company aims to create an accessible therapy for all patients regardless of geography, age, or comorbidities, while avoiding dependence, sedation, or psychotic side effects.

BiotechDigital HealthMental Health

Founders & leadership

DCDelphine Charvin
Delphine CharvinFounding Chief Executive Officer & Board DirectorShe previously served as Chief Scientific Officer at Prexton Therapeutics (acquired by Lundbeck for $1.1 billion), Chief Scientific Officer at Lundbeck, and Chief Scientific Officer and Chief Innovation Officer at Stalicla, and holds 15 years of experience in drug discovery, clinical development, and biotech company building.
MRMélanie Rouillier
Mélanie RouillierVP, Chief Operations Officer & Co-FounderMélanie Rouillier is a PMP-certified drug discovery project manager with 17 years of experience in small-molecule drug discovery from library screening through the pre-clinical phase, including 11 years of scientific project management across public-private partnership and startup-studio settings and expertise in in vitro assay development and identifying allosteric modulators targeting GPCRs in central nervous system diseases. She is VP, Chief Operating Officer, and co-founder of Elkedonia, a biotech company developing an antidepressant that targets intracellular neuroplasticity pathways.
JC
Jocelyne CabochePresident of the Scientific Advisory Board & Co-FounderJocelyne Caboche is a research director at the CNRS and neurobiologist with expertise in psychiatric disease, including addiction, depression, and anxiety disorders. She co-founded Elkedonia to translate neuroscience research into therapeutic strategies for mood and psychiatric conditions.

Investors · 4

CARMA FUNDlisted by CARMA FUNDMunich

How we know: CARMA FUND's portfolio page · Not right? Tell us

Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · a partner's Signal profile · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Sambrinvestlisted by SambrinvestCharleroi

How we know: Sambrinvest's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeed RoundJul 2025
    Source ↗
  • Undisclosed amountSeed RoundJun 2025 · 3 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Elkedonia Closes EUR 11M in Seed Fundingfinsmes.com · Jun 2025

Frequently asked questions

What does Elkedonia do?
Elkedonia is a biotech company developing a novel antidepressant treatment that targets intracellular neuroplasticity pathways rather than synaptic mechanisms, with the goal of providing rapid, long-lasting relief for depression patients. The company aims to create an accessible therapy for all patients regardless of geography, age, or comorbidities, while avoiding dependence, sedation, or psychotic side effects.
Who founded Elkedonia?
Elkedonia was founded by Delphine Charvin, Mélanie Rouillier, Jocelyne Caboche.
Who are Elkedonia's investors?
Elkedonia's investors include Angelini Ventures, CARMA FUND, Kurma Partners, Sambrinvest.